The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

NEW YORK, May 19, 2025 /PRNewswire/ --The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during ...

WHAT'S NEXT? If you suffered a loss in Sana Biotechnology, Inc. during the relevant time frame, you have until May 20, 2025 to request that the Court appoint you as lead plaintiff. Your ability ...

Sana Biotechnology (NASDAQ:SANA – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports.

Sana Biotechnology (NASDAQ:SANA) was upgraded to Market Outperform from Market Perform at Citizens as the research broker believes the company's stock is undervalued, despite its Q4 results ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Sana Biotechnology, Inc. (NASDAQ:SANA) stands ...

Fintel reports that on January 8, 2025, TD Cowen upgraded their outlook for Sana Biotechnology (NasdaqGS:SANA) from Hold to Buy. Analyst Price Forecast Suggests 518.18% Upside As of December 23 ...

Clinical-stage biotech concern Sana Biotechnology, Inc. is headquartered in Seattle, WA. The company is focused on developing candidates off its ex vivo and in vivo cell engineering platforms to ...

On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sana Biotechnology (NASDAQ:SANA), reducing the price target to $8 from the previous $11 while maintaining a Buy rating. The firm's ...